Drug Profile
Research programme: cancer therapeutics - Protox Therapeutics
Alternative Names: LH1; Lung-H1; PORxin™ Ab; PORxin™ antibody fusion constructsLatest Information Update: 22 Sep 2021
Price :
$50
*
At a glance
- Originator National Research Council Canada; University of Victoria
- Developer Sophiris Bio
- Class
- Mechanism of Action Cell membrane modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 02 Apr 2012 Protox Therapeutics is now called Sophiris Bio
- 02 Apr 2012 Discontinued for Cancer in Canada (Parenteral)
- 11 Jun 2007 Early research for cancer is ongoing